- Home
- TXRH vs RPRX Comparison
TXRH vs RPRX Comparison
Compare TXRH & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXRH
- RPRX
- Stock Information
- Founded
- TXRH 1993
- RPRX 1996
- Country
- TXRH United States
- RPRX United States
- Employees
- TXRH N/A
- RPRX N/A
- Industry
- TXRH Restaurants
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- TXRH Consumer Discretionary
- RPRX Health Care
- Exchange
- TXRH Nasdaq
- RPRX Nasdaq
- Market Cap
- TXRH 12.5B
- RPRX 11.7B
- IPO Year
- TXRH 2004
- RPRX 2020
- Fundamental
- Price
- TXRH $182.58
- RPRX $25.23
- Analyst Decision
- TXRH Buy
- RPRX Strong Buy
- Analyst Count
- TXRH 26
- RPRX 6
- Target Price
- TXRH $186.75
- RPRX $41.67
- AVG Volume (30 Days)
- TXRH 675.4K
- RPRX 3.2M
- Earning Date
- TXRH 02-13-2025
- RPRX 02-13-2025
- Dividend Yield
- TXRH 1.34%
- RPRX 3.33%
- EPS Growth
- TXRH 33.83
- RPRX 518.56
- EPS
- TXRH 5.82
- RPRX 2.55
- Revenue
- TXRH $5,099,779,000.00
- RPRX $2,266,003,000.00
- Revenue This Year
- TXRH $17.78
- RPRX $12.21
- Revenue Next Year
- TXRH $9.53
- RPRX $11.13
- P/E Ratio
- TXRH $31.37
- RPRX $9.88
- Revenue Growth
- TXRH 13.91
- RPRX N/A
- 52 Week Low
- TXRH $115.48
- RPRX $24.05
- 52 Week High
- TXRH $206.04
- RPRX $31.66
- Technical
- Relative Strength Index (RSI)
- TXRH 39.83
- RPRX 43.88
- Support Level
- TXRH $178.50
- RPRX $24.05
- Resistance Level
- TXRH $195.71
- RPRX $25.28
- Average True Range (ATR)
- TXRH 3.76
- RPRX 0.55
- MACD
- TXRH -1.60
- RPRX 0.00
- Stochastic Oscillator
- TXRH 20.22
- RPRX 46.46
About TXRH Texas Roadhouse Inc.
Texas Roadhouse Inc is a restaurant company operating predominately in the casual dining segment. The company's operating segment includes Texas Roadhouse; Bubba's 33 and others. It generates maximum revenue from the Texas Roadhouse segment.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.